REVIVEPEPTIDES
0

A use with decades of trials and an uncertain verdict, as the systematic reviews state it

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
The ovary expresses growth hormone and IGF-1 receptors, and from the late 1980s trials added growth hormone to ovarian stimulation in women with poor response to IVF, on the hypothesis that it would improve oocyte number or quality. Cochrane systematic reviews, most recently updated in the 2020s, have found that in poor responders the hormone may increase live birth rate, but that the evidence is of low or very low quality, from small trials with inconsistent definitions, and that in unselected women there is no benefit. The question has been open for thirty years and remains so.

The rationale

Granulosa cells respond to IGF-1, which amplifies the action of follicle-stimulating hormone, and growth hormone raises local and circulating IGF-1. In animal models the hormone improved follicular development. The clinical hypothesis followed directly and was tested in small trials in several countries from 1988 onward.

Poor response — few follicles despite high stimulation — is where the hypothesis was most often tested.

The reviews

Cochrane reviews have pooled a dozen or more trials with a few hundred women in total. Point estimates for live birth in poor responders favour the hormone, with wide confidence intervals and downgraded certainty for risk of bias and imprecision. For women with normal response, no effect. The reviews call for larger trials, which have been slow to appear because the hormone is expensive and the population small.

Professional guidelines describe the use as unproven.

Why it is here

Because it is a part of the clinical literature on the hormone that a thorough account should include, and because its uncertainty is the honest summary. This page describes trials and reviews; it describes no use of the pack.

Somatropin is supplied by REVIVE LAB UAE for laboratory research use only, with identity and purity documented for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
HGH Somatropin Pack24 mg (72 IU)AED 850In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The rationale?

Granulosa cells respond to IGF-1, which amplifies the action of follicle-stimulating hormone, and growth hormone raises local and circulating IGF-1. In animal models the hormone improved follicular development. The clinical hypothesis followed directly and was tested in small trials in several countries from 1988 onward.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

HGH Somatropin Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

→ HGH Somatropin Pack — 24 mg (72 IU) → Approved indications: the regulatory list → The GH-IGF-1 axis: a research primer

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.